Ainos Inc. (AIMD)
NASDAQ (CM) NASDAQ (CM) Primary 
Ainos Concludes Growth Financing From Lind Partners
Maintaining robust financial runway after the prepayment Reinforcing Ainos' commitment towards building shareholder value SAN DIEGO, CA / ACCESSWIRE / August 6, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA"), today announced that the Company has prepaid its remaining convertible note financing (the "Note") with Lind Global Fund II LP, an institutional investment fund managed by The Lind Partners (together the "Investor"), through conversions of the Note by the Investor and payments by the Company, which aggregates at a total of approximately US$1.67 million. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and CEO of Ainos, commented, "We remain extremely appreciative of the financial support from The Lind Partners, which provided us the growth capital to execute our VELDONA and AI Nose development plans.
Ainos Reports Second Quarter 2024 Financial Results
Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developments Robust financial runway for over 12 months following the prepayment of a senior secured convertible note SAN DIEGO, CA / ACCESSWIRE / August 5, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA®"), today announced its financial results for the second quarter ended June 30, 2024. Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We've made meaningful progress in initiating a clinical study for treating feline chronic gingivostomatitis ("FCGS").
Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug
The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market. This clinical trial aims to complete the enrollment of 30 subjects by the end-2024 with the trial report to be finalized in Q1 2025.
